{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:47:34Z","timestamp":1755222454126,"version":"3.43.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,10]]},"DOI":"10.7759\/cureus.89750","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T01:34:23Z","timestamp":1754876063000},"source":"Crossref","is-referenced-by-count":0,"title":["Roxadustat Activates Thyroid Hormone Receptors \u03b1 and \u03b2 at Clinically Relevant Concentrations"],"prefix":"10.7759","author":[{"given":"Koji","family":"Morita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Iigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaho","family":"Jimbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Jimbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Edo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Uno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-017-0046-z","article-title":"A clinician's guide to understanding resistance to thyroid hormone due to receptor mutations in the TR\u03b1 and TR\u03b2 isoforms","volume":"3","author":"Singh BK","year":"2017","unstructured":"Singh BK, Yen PM. A clinician's guide to understanding resistance to thyroid hormone due to receptor mutations in the TR\u03b1 and TR\u03b2 isoforms. Clin Diabetes Endocrinol. 2017, 3:8. 10.1186\/s40842-017-0046-z","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0071","article-title":"Thyroid hormone analogues: an update","volume":"30","author":"Zucchi R","year":"2020","unstructured":"Zucchi R. Thyroid hormone analogues: an update. Thyroid. 2020, 30:1099-105. 10.1089\/thy.2020.0071","journal-title":"Thyroid"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective thyroid hormone receptor-beta (TR\u03b2) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders","volume":"7","author":"Saponaro F","year":"2020","unstructured":"Saponaro F, Sestito S, Runfola M, Rapposelli S, Chiellini G. Selective thyroid hormone receptor-beta (TR\u03b2) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders. Front Med (Lausanne). 2020, 7:331. 10.3389\/fmed.2020.00331","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al.. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024, 390:497-509. 10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne DW","year":"2021","unstructured":"Coyne DW, Roger SD, Shin SK, et al.. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021, 6:624-35. 10.1016\/j.ekir.2020.11.034","journal-title":"Kidney Int Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.10.002","article-title":"Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance","volume":"20","author":"Yao B","year":"2019","unstructured":"Yao B, Wei Y, Zhang S, et al.. Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance. iScience. 2019, 20:489-96. 10.1016\/j.isci.2019.10.002","journal-title":"iScience"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/endo-105-1-80","article-title":"Depletion of L-3,5,3'-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone","volume":"105","author":"Samuels HH","year":"1979","unstructured":"Samuels HH, Stanley F, Casanova J. Depletion of L-3,5,3'-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology. 1979, 105:80-5. 10.1210\/endo-105-1-80","journal-title":"Endocrinology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0293","article-title":"Comparison of thyroidectomized calf serum and stripped serum for the study of thyroid hormone action in human skin fibroblasts in vitro","volume":"19","author":"Moeller LC","year":"2009","unstructured":"Moeller LC, Wardrip C, Niekrasz M, Refetoff S, Weiss RE. Comparison of thyroidectomized calf serum and stripped serum for the study of thyroid hormone action in human skin fibroblasts in vitro. Thyroid. 2009, 19:639-44. 10.1089\/thy.2008.0293","journal-title":"Thyroid"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.thscie.2024.100010","article-title":"Indocyanine green rapidly inhibits triiodothyronine-induced gene transcription","volume":"1","author":"Morita K","year":"2024","unstructured":"Morita K, Suzuki T, Terakawa A, et al.. Indocyanine green rapidly inhibits triiodothyronine-induced gene transcription. Thyroid Science. 2024, 1:100010. 10.1016\/j.thscie.2024.100010","journal-title":"Thyroid Science"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02304-2","article-title":"Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis","volume":"22","author":"Ichii M","year":"2021","unstructured":"Ichii M, Mori K, Miyaoka D, et al.. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrol. 2021, 22:104. 10.1186\/s12882-021-02304-2","journal-title":"BMC Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab007","article-title":"Roxadustat and thyroid-stimulating hormone suppression","volume":"14","author":"Tokuyama A","year":"2021","unstructured":"Tokuyama A, Kadoya H, Obata A, Obata T, Sasaki T, Kashihara N. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021, 14:1472-4. 10.1093\/ckj\/sfab007","journal-title":"Clin Kidney J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.24.0319","article-title":"Central hypothyroidism caused by roxadustat","volume":"144","author":"Hauge JW","year":"2024","unstructured":"Hauge JW, W\u00e6rp CM, Hofs\u00f8 D, Abedini S. Central hypothyroidism caused by roxadustat. Tidsskr Nor Laegeforen. 2024, 144:10.4045\/tidsskr.24.0319","journal-title":"Tidsskr Nor Laegeforen"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61843","article-title":"Roxadustat-induced central hypothyroidism in renal anemia patients: insights from antineutrophil cytoplasmic antibody-related vasculitis cases","volume":"16","author":"Omote D","year":"2024","unstructured":"Omote D, Kuramoto N, Tomikawa A, Yasui M, Fukuta M, Hiraguri M. Roxadustat-induced central hypothyroidism in renal anemia patients: insights from antineutrophil cytoplasmic antibody-related vasculitis cases. Cureus. 2024, 16:e61843. 10.7759\/cureus.61843","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76499","article-title":"Roxadustat-induced central hypothyroidism masked by uremia at the initiation of hemodialysis: a case report","volume":"16","author":"Hashimoto M","year":"2024","unstructured":"Hashimoto M, Nagayama Y, Ichikura-Iida A, Inoue T. Roxadustat-induced central hypothyroidism masked by uremia at the initiation of hemodialysis: a case report. Cureus. 2024, 16:e76499. 10.7759\/cureus.76499","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9400","article-title":"Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat","volume":"12","author":"Kita S","year":"2024","unstructured":"Kita S, Okuyama H, Kondo T, et al.. Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat. Clin Case Rep. 2024, 12:e9400. 10.1002\/ccr3.9400","journal-title":"Clin Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2199093","article-title":"Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study","volume":"45","author":"Zheng X","year":"2023","unstructured":"Zheng X, Jin Y, Xu T, Xu H, Zhu S. Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study. Ren Fail. 2023, 45:2199093. 10.1080\/0886022X.2023.2199093","journal-title":"Ren Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad017","article-title":"Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients","volume":"38","author":"Cheng Y","year":"2023","unstructured":"Cheng Y, Xiang Q, Cao T, et al.. Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients. Nephrol Dial Transplant. 2023, 38:1567-70. 10.1093\/ndt\/gfad017","journal-title":"Nephrol Dial Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad483","article-title":"Effect of roxadustat on thyroid function in patients with renal anemia","volume":"109","author":"Haraguchi T","year":"2023","unstructured":"Haraguchi T, Hamamoto Y, Kuwata H, et al.. Effect of roxadustat on thyroid function in patients with renal anemia. J Clin Endocrinol Metab. 2023, 109:e69-75. 10.1210\/clinem\/dgad483","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2300","article-title":"Disproportionality analysis on hypothyroidism with roxadustat using the Japanese Adverse Drug Event Database","volume":"63","author":"Kouki Y","year":"2023","unstructured":"Kouki Y, Okada N, Saga K, Ozaki M, Saisyo A, Kitahara T. Disproportionality analysis on hypothyroidism with roxadustat using the Japanese Adverse Drug Event Database. J Clin Pharmacol. 2023, 63:1141-6. 10.1002\/jcph.2300","journal-title":"J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-024-00351-z","article-title":"Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis","volume":"10","author":"Nakano Y","year":"2024","unstructured":"Nakano Y, Mitsuboshi S, Tada K, Masutani K. Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis. J Pharm Health Care Sci. 2024, 10:30. 10.1186\/s40780-024-00351-z","journal-title":"J Pharm Health Care Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.97599","article-title":"Effects of roxadustat on thyroid hormone levels and blood lipid metabolism in patients undergoing hemodialysis: a retrospective study","volume":"21","author":"Li N","year":"2024","unstructured":"Li N, Cui W, Mu D, et al.. Effects of roxadustat on thyroid hormone levels and blood lipid metabolism in patients undergoing hemodialysis: a retrospective study. Int J Med Sci. 2024, 21:1806-13. 10.7150\/ijms.97599","journal-title":"Int J Med Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13519","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: an analysis of the Japanese Pharmacovigilance Database","volume":"38","author":"Tanaka H","year":"2024","unstructured":"Tanaka H, Tani A, Onoda T, Ishii T. Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: an analysis of the Japanese Pharmacovigilance Database. In Vivo. 2024, 38:917-22. 10.21873\/invivo.13519","journal-title":"In Vivo"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2410375","article-title":"Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study","volume":"46","author":"Otsuka E","year":"2024","unstructured":"Otsuka E, Kitamura M, Funakoshi S, Mukae H, Nishino T. Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study. Ren Fail. 2024, 46:2410375. 10.1080\/0886022X.2024.2410375","journal-title":"Ren Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000542699","article-title":"Effects of roxadustat on thyroid profiles in patients and animals with chronic kidney disease","volume":"56","author":"Li W","year":"2025","unstructured":"Li W, Cao T, Huang G, et al.. Effects of roxadustat on thyroid profiles in patients and animals with chronic kidney disease. Am J Nephrol. 2025, 56:351-65. 10.1159\/000542699","journal-title":"Am J Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.24.3351","article-title":"Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway","volume":"11","author":"Caelles C","year":"1997","unstructured":"Caelles C, Gonz\u00e1lez-Sancho JM, Mu\u00f1oz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 1997, 11:3351-64. 10.1101\/gad.11.24.3351","journal-title":"Genes Dev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00038.2019","article-title":"Nongenomic actions of thyroid hormone: the integrin component","volume":"101","author":"Davis PJ","year":"2021","unstructured":"Davis PJ, Mousa SA, Lin HY. Nongenomic actions of thyroid hormone: the integrin component. Physiol Rev. 2021, 101:319-52. 10.1152\/physrev.00038.2019","journal-title":"Physiol Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389447-roxadustat-activates-thyroid-hormone-receptors--and--at-clinically-relevant-concentrations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T01:34:26Z","timestamp":1754876066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389447-roxadustat-activates-thyroid-hormone-receptors--and--at-clinically-relevant-concentrations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,10]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.89750","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,10]]}}}